Literature DB >> 15876585

Mutational analysis of the BRCA1 gene in 30 Czech ovarian cancer patients.

M Zikan1, P Pohlreich, J Stribrna.   

Abstract

Ovarian cancer is one of the most severe of oncological diseases. Inherited mutations in cancer susceptibility genes play a causal role in 5-10% of newly diagnosed tumours. BRCA1 and BRCA2 gene alterations are found in the majority of these cases. The aim of this study was to analyse the BRCA1 gene in the ovarian cancer risk group to characterize the spectrum of its mutations in the Czech Republic. Five overlapping fragments amplified on both genomic DNA and cDNA were used to screen for the whole protein-coding sequence of the BRCA1 gene. These fragments were analysed by the protein truncation test (PTT) and direct sequencing. Three inactivating mutations were identified in the group of 30 Czech ovarian cancer patients: the 5382insC mutation in two unrelated patients and a deletion of exons 21 and 22 in another patient. In addition, we have found an alternatively spliced product lacking exon 5 in two other unrelated patients. The 5382insC is the most frequent alteration of the BRCA1 gene in Central and Eastern Europe. The deletion of exons 21 and 22 affects the BRCT functional domain of the BRCA1 protein. Although large genomic rearragements are known to be relatively frequent in Western European populations, no analyses have been performed in our region yet.

Entities:  

Mesh:

Year:  2005        PMID: 15876585     DOI: 10.1007/bf02715891

Source DB:  PubMed          Journal:  J Genet        ISSN: 0022-1333            Impact factor:   1.166


  26 in total

1.  In-frame deletions of BRCA1 may define critical functional domains.

Authors:  E M Rohlfs; C H Chung; Q Yang; C Skrzynia; W W Grody; M L Graham; L M Silverman
Journal:  Hum Genet       Date:  2000-10       Impact factor: 4.132

2.  BRCA1 is a component of the RNA polymerase II holoenzyme.

Authors:  R Scully; S F Anderson; D M Chao; W Wei; L Ye; R A Young; D M Livingston; J D Parvin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

3.  BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.

Authors:  Magdalena Perkowska; Izabela BroZek; Barbara Wysocka; Karin Haraldsson; Therese Sandberg; Ulla Johansson; Gunilla Sellberg; Ake Borg; Janusz Limon
Journal:  Hum Mutat       Date:  2003-05       Impact factor: 4.878

Review 4.  BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.

Authors:  P L Welcsh; M C King
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

5.  [Detection and occurrence of BRCA 1 gene mutation in patients with carcinoma of the breast and ovary].

Authors:  N Jancárková; M Zikán; P Pohlreich; P Freitag; B Matous; J Zivný
Journal:  Ceska Gynekol       Date:  2003-01

6.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

Authors:  D Shattuck-Eidens; A Oliphant; M McClure; C McBride; J Gupte; T Rubano; D Pruss; S V Tavtigian; D H Teng; N Adey; M Staebell; K Gumpper; R Lundstrom; M Hulick; M Kelly; J Holmen; B Lingenfelter; S Manley; F Fujimura; M Luce; B Ward; L Cannon-Albright; L Steele; K Offit; A Thomas
Journal:  JAMA       Date:  1997-10-15       Impact factor: 56.272

7.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

8.  Detection of the most frequent mutations in BRCA1 gene on polyacrylamide gels containing Spreadex Polymer NAB.

Authors:  M Janatová; P Pohlreich; B Matous
Journal:  Neoplasma       Date:  2003       Impact factor: 2.575

9.  A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.

Authors:  O Serova; M Montagna; D Torchard; S A Narod; P Tonin; B Sylla; H T Lynch; J Feunteun; G M Lenoir
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

10.  Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA).

Authors:  Carmel Apicella; Lesley Andrews; Shirley V Hodgson; Sheila A Fisher; Cathryn M Lewis; Ellen Solomon; Katherine Tucker; Michael Friedlander; Agnes Bankier; Melissa C Southey; Deon J Venter; John L Hopper
Journal:  Breast Cancer Res       Date:  2003-08-28       Impact factor: 6.466

View more
  4 in total

1.  On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations.

Authors:  Nancy Hamel; Bing-Jian Feng; Lenka Foretova; Dominique Stoppa-Lyonnet; Steven A Narod; Evgeny Imyanitov; Olga Sinilnikova; Laima Tihomirova; Jan Lubinski; Jacek Gronwald; Bohdan Gorski; Thomas v O Hansen; Finn C Nielsen; Mads Thomassen; Drakoulis Yannoukakos; Irene Konstantopoulou; Vladimir Zajac; Sona Ciernikova; Fergus J Couch; Celia M T Greenwood; David E Goldgar; William D Foulkes
Journal:  Eur J Hum Genet       Date:  2010-12-01       Impact factor: 4.246

2.  High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer.

Authors:  Michal Zikan; Marketa Janatova; David Pavlista; Petr Pohlreich
Journal:  J Genet       Date:  2007-08       Impact factor: 1.166

3.  Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine.

Authors:  I Gorodetska; S Serga; T Lahuta; L Ostapchenko; S Demydov; N Khranovska; O Skachkova; M Inomistova; O Kolesnik; V Svintsitsky; N Tsip; A Peresunko; N Kmit'; O Manzhura; Z Rossokha; O Popova; H Salomakhina; S Kyriachenko; I Kozeretska
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

4.  High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients.

Authors:  Evgeny N Suspitsin; Nathalia Yu Sherina; Daria N Ponomariova; Anna P Sokolenko; Aglaya G Iyevleva; Tatyana V Gorodnova; Olga A Zaitseva; Olga S Yatsuk; Alexandr V Togo; Nathalia N Tkachenko; Grigory A Shiyanov; Oksana S Lobeiko; Nadezhda Yu Krylova; Dmitry E Matsko; Sergey Ya Maximov; Adel F Urmancheyeva; Nathalia V Porhanova; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2009-02-25       Impact factor: 2.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.